Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Buys 3,802 Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. bought 3,802 shares of the stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average cost of $24.97 per share, with a total value of $94,935.94. Following the completion of the purchase, the insider directly owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. This trade represents a 0.06% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 20th, Ra Capital Management, L.P. acquired 996 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Down 0.6%

COAG stock traded down $0.17 during midday trading on Thursday, reaching $26.30. The company’s stock had a trading volume of 193,388 shares, compared to its average volume of 251,804. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.00 and a 52 week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.